Tumor microenvironment confers mTOR inhibitor resistance in invasive intestinal adenocarcinoma

Antitumor activity of the MEK inhibitor trametinib on intestinal polyp formation inApcΔ716mice involves stromal COX-2

(2015) Teruaki Fujishita et al.   CANCER SCIENCE

HSP90 inhibitor AUY922 abrogates up-regulation of RTKs by mTOR inhibitor AZD8055 and potentiates its antiproliferative activity in human breast cancer

(2014) Si-Meng Chen et al.   INTERNATIONAL JOURNAL OF CANCER

Targeted Therapy for Breast Cancer

(2013) Ali Mohamed et al.   AMERICAN JOURNAL OF PATHOLOGY

Combination of mTOR and EGFR Kinase Inhibitors Blocks mTORC1 and mTORC2 Kinase Activity and Suppresses the Progression of Colorectal Carcinoma

(2013) Quan Wang et al.   PLoS One

Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics

(2012) Y Kanda   BONE MARROW TRANSPLANTATION

Enhanced Apoptosis and Tumor Growth Suppression Elicited by Combination of MEK (Selumetinib) and mTOR Kinase Inhibitors (AZD8055)

(2012) S. V. Holt et al.   CANCER RESEARCH

mTOR Signaling in Growth Control and Disease

(2012) Mathieu Laplante et al.   CELL

The Behavior of Matrix Metalloproteinases and Their Inhibitors in Colorectal Cancer

(2012) László Herszényi et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

The inflammatory network in the gastrointestinal tumor microenvironment: lessons from mouse models

(2012) Hiroko Oshima et al.   JOURNAL OF GASTROENTEROLOGY

mTOR Kinase Inhibitor AZD8055 Enhances the Immunotherapeutic Activity of an Agonist CD40 Antibody in Cancer Treatment

(2011) Q. Jiang et al.   CANCER RESEARCH

JNK Signaling Promotes Intestinal Tumorigenesis Through Activation of mTOR Complex 1 in ApcΔ716 Mice

(2011) Teruaki Fujishita et al.   GASTROENTEROLOGY

Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy

(2011) Seth A. Wander et al.   JOURNAL OF CLINICAL INVESTIGATION

Phosphoproteomic Analysis Identifies Grb10 as an mTORC1 Substrate That Negatively Regulates Insulin Signaling

(2011) Y. Yu et al.   SCIENCE

The mTOR-Regulated Phosphoproteome Reveals a Mechanism of mTORC1-Mediated Inhibition of Growth Factor Signaling

(2011) P. P. Hsu et al.   SCIENCE

mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT Signaling

(2011) V. S. Rodrik-Outmezguine et al.   Cancer Discovery

Dvl2 Promotes Intestinal Length and Neoplasia in the ApcMin Mouse Model for Colorectal Cancer

(2010) C. Metcalfe et al.   CANCER RESEARCH

AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity

(2009) C. M. Chresta et al.   CANCER RESEARCH

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

(2008) Robert J Motzer et al.   LANCET

Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in Apc 716 mice

(2008) T. Fujishita et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation

(2008) A. Y. Choo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA